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Background: TheDanishmultidisciplinary renal cancer group (DaRenCa) established the nation-
wide database DaRenCaData in 2010. The Danish Cancer Registry (DCR) has been considered the
golden standard. In contrast to DCR, DaRenCaData required the diagnosis to be histologically or
cytologically verified. DaRenCaData and DCR have not previously been compared.
Patients and Methods: We included patients with renal cell carcinoma registered in
DaRenCaData and/or DCR from August 1st 2010 to December 31st 2015. We computed
completeness and positive predictive value (PPV) of a diagnosis in DaRenCaData compared
with DCR, 1-year, 3-year and 5-year mortality rate ratios, and relative survival.
Results: We identified 4890 patients in the two registries. Of these, 4326 were registered in
DaRenCaData and 4714 in DCR. Completeness of DaRenCaData was 88% [95% CI, 87–89%]
and increased during the period from 82% to 94%. The PPVwas 96% [95%CI, 95–97%]. A total
of 4150 patients (85%) were found in both registries, 4% (176 patients) in DaRenCaData only,
and 12% (564 patients) in DCR only. The relative survival was higher for patients in
DaRenCaData vs DCR; the 1-year and 5-year relative survival was 85% vs 81% and 65% vs
59%, respectively. Compared with patients registered in both registries, the mortality rates were
higher in patients registered in DaRenCaData only (1-year hazard ratio (HR)=2.84 [95% CI,
2.20–3.68]) or DCR only (1-year HR=4.29 [95% CI, 3.72–4.93]). Observed in both registries,
survival improved over time with a 7% yearly reduction in death based on estimations of 1-year
mortality rate ratios.
Conclusion: DaRenCaData had high and increasing completeness and high PPV, establish-
ing it as a high-quality research database. Observed in both registries, renal cell carcinoma
mortality declined over time; patients only registered in DCR or DaRenCaData had poorer
outcomes. This study points to the importance of assessing the inclusion criteria when
interpreting registry-based studies.
Keywords: kidney cancer, national registries, survival, assessment of database
Introduction
Denmark has several population-based clinical databases comprising routinely
collected health-related data.1,2 Among these databases, the multidisciplinary
Danish Renal Cancer Group (DaRenCa) established a nationwide database
(DaRenCaData) in 2010 with the primary objective to monitor the clinical quality
of renal cell carcinoma diagnostics and treatment in Denmark.3 So far, the data
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quality of DaRenCaData has not been formally assessed.
The Danish Cancer Registry (DCR) is a well-established
nationwide registry that has monitored incidence and sur-
vival of all Danish cancer cases since 1943.4 Both regis-
tries contain details of new cases obtained through
automatized linkage between national registries, ie, the
Danish National Patient Register (DNPR), the Danish
Pathology Register (DPR), and the Civil Registration
System; however, inclusion criteria vary slightly.
DaRenCaData focuses only on histologically or cytologi-
cally verified kidney cancer in patients with a diagnosis in
the hospital system; the registry contains data on diagno-
sis, treatments, outcomes, and a few variables registered
online in a web-based form by the treating clinicians.3 The
DCR contains data on cancer diagnosis and outcomes; the
registry additionally receives notifications from the
National Causes of Death Registry and from general prac-
titioners and practising specialists outside the hospitals.4
The existence of two nationwide Danish registries on renal
cell carcinoma made it possible to assess the data quality
in DaRenCaData in comparison to DCR. To perform an
evaluation of registration overlap and impact of differ-
ences in inclusion criteria on survival measures is crucial
for adequate use and understanding of research employing
either of the two data sources.5–7
The present study was established as a collaboration
between the Danish Cancer Registry, DaRenCa, and the
Danish Cancer Society Research Center and aimed to: 1)
assess the quality of DaRenCaData by completeness of
data and the positive predictive value (PPV) compared
with the DCR, 2) identify discrepancies between
DaRenCaData and DCR, and 3) quantify the impact of
potential discrepancies on the survival estimates. Thereby,
the study may contribute to the growing body of literature
regarding assessments of the quality of data from clinical
databases5–7 presenting DaRenCaData as a data source,
which can be useful for future clinical research.
Patients and Methods
Data Sources
DaRenCaData included all persons with a first-time diag-
nosis of renal cancer in Denmark since August 2010. The
renal cell carcinoma diagnosis was required to be histolo-
gically or cytologically verified. Patients were identified if
they had a first-time registration of a renal cancer in the
DPR, which contains information using SNOMED codes
on all samples examined at Danish departments of
pathology.8 Patients were included in DaRenCaData if
they had either (a) a code indicating a tumour in the
kidney (SNOMED code “T71*”) followed immediately
on the same material by a code indicating a malignant
carcinoma (an M-code ending on “3” in the interval
M80103-M958*3 – excluding nephroblastoma (M89603)
and urothelial carcinoma (M81203)) – or (b) a code indi-
cating a metastasis from a renal tumour (code “ÆF4510”
unless the ÆF4510-code was proceeded by “M81206”).
Patients were not included in DaRenCaData if the diag-
nosis was tentative (if the relevant M-code or ÆF4510-
code was followed by “ÆYYY00”), or if the cancer was
a relapse. The diagnosis was considered a relapse if the
patient had a prior diagnosis of renal cell carcinoma iden-
tified either from notes in DaRenCaData or from registra-
tions in DPR or in the DNPR, which recorded information
on diagnoses and treatment in Danish somatic hospitals
since 1977.9 DaRenCaData did not include patients whose
diagnoses were solely recorded from death certificates
(death certificate only; DCOs). The date of diagnosis in
DaRenCaData was defined as the date the biopsy or surgi-
cal treatment was performed.
DCR is a nationwide cancer registry that was estab-
lished in 1943, administered by the Danish Health Data
Authority. It is considered to hold data for all incident
cancer cases in Denmark, including information on tumour
characteristics, eg, ICD10 codes, topology, morphology,
laterality, stage, grade, and date of diagnosis.4 For DCR,
the primary data sources were registrations in DNPR and
death certificates. DCR considered all patients diagnosed
with ICD-10 code C64 as patients with renal cell carci-
noma. Following identification of a patient in DNPR, DCR
looked for supplementary information from DPR; how-
ever, the diagnosis did not have to be histologically or
cytologically verified. Thus, DCR may identify patients
with renal cell carcinoma if they were only diagnosed by
imaging and not by biopsy or fine needle aspiration, and as
such not found in DPR. The date of diagnosis in DCR was
defined as the date of the first hospital contact where
a diagnosis of renal cancer was registered in DNPR.
Since 1968 all residents in Denmark have been equipped
with a unique individual ten digits personal code (a CPR-
number). This number, unique to each Danish resident, is
used in all Danish registries, allowing unambiguous indivi-
dual-level data linkage. From the Civil Registration System,
we obtained information on vital status (dead or alive), date
of death, and residence for all cancer patients.10
Danckert et al Dovepress
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This study was approved by the Danish Data Protection
Agency (2015-41-3726) and locally at the Danish Cancer
Society Research Center (2019-DCRC-0059). According
to Danish legislation, this registry-based study did not
require further ethical approval because it did not involve
any patient contact or intervention.
Patient Cohort
The present study included all patients with renal cell
carcinoma who were permanent residents in Denmark
and registered in DCR or DaRenCaData during the period
August 1st 2010 to December 31st 2015. The study period
ended on December 31st 2015, because a new IT system
was introduced in two Danish regions during 2016 and
2017 which may have caused irregularities in registrations.
A calendar year for DaRenCaData spanned from
August 1st to July 31th the subsequent year.
Statistical Methods
The completeness of data in the DaRenCaData relative to
DCR was estimated, indicating the number of patients
with renal cell carcinoma in DCR who were also regis-
tered in DaRenCaData.11 Furthermore, the positive predic-
tive value (PPV) of the data in DaRenCaData was
calculated and defined as the number of patients in
DaRenCaData who were also registered with renal cell
carcinoma in DCR.11 Registrations in DCR and
DaRenCaData were considered identical if the patients
had the same CPR-number and were recorded in both
registries with no more than 120 days between the regis-
tered dates of diagnosis.
Data in the two registries were merged, and agreement
in the data sets was assessed by inspecting the size of the
intersection (denoting patients found in both registries),
while differences were assessed by inspecting the
DaRenCaData set difference (observations only found in
DaRenCaData) and the DCR set difference (observations
only found in DCR). For patients in the set differences, it
was investigated whether the patient appeared with
a registered first incidence of renal cancer in either
DNPR or DPR (or both) within 120 days from the date
of diagnosis recorded in the set difference.
Differences in survival and mortality between patients
in both registries, in the intersection, and the set differ-
ences were investigated by estimating 1-, 3- and 5-year
survival relative to survival of the background population,
and 1-, 3- and 5-year mortality rate ratios (MRRs) for
which the end of follow-up was December 31st 2017.
Relative survival (RS) estimates were obtained based on
the Ederer II weighing method.12 The estimates were
adjusted for age using the International Cancer Survival
Standard population weighs (specifically ICSS1).13
However, contrary to the ICSS standard, a few patients
younger than age 15 were included in DCR and
DaRenCaData, implying that the age groups were 0–44,
45–64, 65–74 and 75+ years old. The estimates of
expected survival were based on population mortality
rates stratified by sex, age, and calendar time (in 1-year
intervals up to an age at 98 years after which all observa-
tions were grouped to age 99+ years). Note that the sizes
of 1-, 3- and 5-year relative survival estimates should not
be compared to each other since they were not based on
the same sample (1-year follow up was available for all
patients which was not the case for all patients with regard
to 3- and 5-year follow up).
MRRs were calculated as hazard ratios (HRs) using
Cox Proportional Hazard models for which the underlying
timescale was time since diagnosis. The estimations
included sex and age at the time of diagnosis as strata
(age was grouped similarly to the relative survival estima-
tions), and adjustments were made for T-stage, N-stage,
M-stage, and combined TNM-stage. The proportional
hazard assumptions were checked, and did not give rise
to any concern. A total of 38 observations were excluded
in the survival and mortality analyses, because the dates of
death preceded the dates of diagnosis in the registration.
Kaplan-Meier curves were generated to visualise survival
across different groups.
For all statistical analyses except relative survival, SAS
statistical software was used. For relative survival, the
statistical software RStudio was used (specifically the
package “popEpi”).14
Results
Patient Cohort
Between August 1st 2010 and December 31st 2015, a total
of 4890 patients with renal cell carcinoma were registered
in the two registries; 4326 patients were recorded in
DaRenCaData, and 4714 patients were identified in DCR
(6 registrations in DaRenCaData were excluded because
they lacked a valid CPR-number).
Of the 4326 patients registered in DaRenCaData, 4150
were registered in DCR as well, yielding a positive pre-
dictive value of being registered in DaRenCaData of 96%
[95% CI, 95–97%]. Of the 4714 patients registered in
Dovepress Danckert et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
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DCR, 4150 were captured in DaRenCaData as well, giving
a completeness of DaRenCaData at 88% [95% CI,
87–89%] (Table 1).
The number of patients per year captured in both
registries increased from 649 patients (82%) in
2010–2011 to 865 patients (94%) in 2014–2015. In all,
564 patients (12%) were found only in the DCR, and this
number decreased over time from 145 patients in
2010–2011 to 57 patients in 2014–2015. Patients only
found in DaRenCaData comprised 4% (n=176), and the
number per year was rather stable during the study period.
Patients Found Only in DaRenCaData
Of the 176 patients registered only in the DaRenCaData
(Table 1), 24 (14%) patients were also registered in DCR,
but before or after the specified study time period. Of the
176 patients, 148 (84%) patients were registered in DPR
with a diagnosis of renal cell carcinoma, and therefore
seemed to be candidates also for inclusion in DCR. For 4
(<0.1%) patients registered only in DaRenCaData, there
was no renal cancer diagnosis recorded based on the
SNOMED codes in DPR with a date of diagnosis within
120 days before or after the DaRenCaData date of diag-
nosis. The source of these records was unknown.
Patients Found Only in DCR
Of the 564 patients registered only in DCR (Table 1), 16
(3%) patients were also registered in DaRenCaData, but
after the study closure time December 31st 2015. Nineteen
patients, corresponding to 0.4% of all patients in DCR,
were likely to be DCOs, as the registered date of diagnosis
was identical to the registered date of death. For 446
(79%) patients, a first incident renal cell carcinoma was
recorded in DNPR within 120 days between the DCR and
DNPR dates of diagnosis, but the diagnosis was not ver-
ified histologically or cytologically as no record appeared
in the DPR. For 45 (8%) patients, DPR confirmed renal
cell carcinoma, thus fulfilling the DaRenCaData inclusion
criteria. For the remaining 38 (7%) patients registered only
in DCR, no coding of the first instance of renal cancer
diagnosis was recorded neither in DNPR nor in DPR
within 120 days from the DCR dates of diagnosis.
Patients registered in DCR only were older (median;
5–95 percentiles), with age 74 years (48–90) compared
with both registries 66 years (45–82), or DaRenCaData
only 68 years (49–84). There was no significant difference
in sex distribution between patients in DCR only,
DaRenCaData only, or both registries.
Comparison of Relative Survival
Estimates
The relative survival of patients registered in
DaRenCaData was higher compared to patients registered
in DCR: The 1-year relative survival was 85% [95% CI:
84–86%] vs 81% [95% CI: 79–82%], 3-year relative sur-
vival was 74% [95% CI: 73–76%] vs 69% [95% CI:
67–70%], and 5-year relative survival was 65% [95% CI:
63–67%] vs 59% [95% CI: 57–61%] (Figure 1A, Table 2).
The 1-year relative survival of patients registered in
both DaRenCaData and DCR was 86%, and was similar
whether the DaRenCaData or DCR date of diagnosis was
used as entry point (Figure 1B). In contrast, the 1-year
relative survival was 64% [95% CI, 56–70%] for patients
in the DaRenCaData only and 52% [95% CI 48–56%] for
patients in DCR only (Figure 1B, Table 2).
Table 1 Completeness and Positive Predictive Value (PPV) of Registrations in DaRenCaData Compared to Registrations in DCR
DaRenCaData –DCR
Patients in Both Registries
DaRenCaData
Only
DCR
Only
Total Completeness PPV
DaRenCaData N DCR N DaRenCa N DCR N % (95% CI) % (95% CI)
01/08/2010–31/07/2011* 649 665 50 145 82 (79–84) 93 (91–95)
01/08/2011–31/07/2012 694 695 26 129 84 (82–87) 96 (95–98)
01/08/2012–31/07/2013 725 715 38 92 89 (87–91) 95 (93–97)
01/08/2013–31/07/2014 849 856 21 93 90 (88–92) 98 (97–99)
01/08/2014–31/07/2015 865 861 24 57 94 (92–95) 97 (96–98)
01/08/2015–31/12/2015 368 358 17 48 88 (85–92) 96 (94–98)
Total 4150 (85%) 176 (4%) 564 (12%) 4890 (100%) 88 (87–89) 96 (95–97)
Notes: *The time periods correspond to the annual reports of DaRenCaData going from August to July; DCR, Danish Cancer Registry; DaRenCaData, Clinical database of
the multidisciplinary renal cancer group; PPV Positive Predictive Value: calculated as patients in the intersection in relation to all patients in DaRenCaData; Completeness:
Calculated as patients in the intersection in relation to all patients in DCR.
Danckert et al Dovepress
submit your manuscript | www.dovepress.com
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Further analyses of 1- and 3-year relative survival
indicated that relative survival improved during the study
period assessed in both DCR and DaRenCaData
(Supplementary Table 1).
Comparing Mortality
The 1-year MRR for all patients in DaRenCaData was sig-
nificantly lower than the MRR for all observations in DCR
(HR = 0.79 [95% CI, 0.72 to 0.88]). Similar findings were
obtained with regard to 3- and 5-year MRRs (Table 3).
Adjusting for stage did not impact findings. Compared with
DCR patient population, 1-year MRR (HR; 95% CI) in
DaRenCaData patient population adjusted for T-stage was
0.88 (0.73–0.89), N-stage 0.78 (0.71–0.86), M-stage 0.81
(0.73–0.89), and combined TNM-stage 0.83 (0.75–0.92);
similar findings were obtained with 5-year MRR as endpoint.
For patients included in both registries, the 1-year MRR was
similar using either the date of diagnosis registered in
DaRenCaData or in DCR as entry point (HR = 0.98 [95%
CI, 0.88 to 1.10]). Patients in the DaRenCaData only and in
Figure 1 (A) Relative survival for two nationwide renal cell carcinoma registries. Kaplan-Meier curves showing the outcomes for patients registered in DaRenCaData and
Danish Cancer Registry. (B) Relative survival based on registry registration. Kaplan-Meier curves showing survival of patients found in both registries (intersection) with
DaRenCaData’s date of diagnosis, or with DCR’s date of diagnosis, registration in DaRenCaData only (DaRenCa set difference) and registration in Danish Cancer Registry
only (DCR set difference).
Dovepress Danckert et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
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the DCR only had significantly higher MRRs (HR = 2.84
[95% CI, 2.20 to 3.68] and 4.29 [95% CI, 3.72 to 4.93],
respectively), than patients registered in both registries using
the DCR date of diagnosis as entry point, with the highest
MRR observed among patients only found in the DCR reg-
istry (Table 3).
The MRRs for patients registered in both
DaRenCaData and DCR declined significantly from
2012–2013 to 2014–2015 with lowest HR for the 1-year
mortality rate at 0.74 [95% CI, 0.63 to 0.87] when com-
pared to patients diagnosed in 2010–2011 (Table 4), and
HR for the 3-year mortality rate at 0.77 [95% CI, 0.68 to
0.87] (Supplementary Table 2). Assessed with time as
a continuous variable, the 1-year MRR was 0.93 [95%
CI, 0.90 to 0.96] (Table 4) (corresponding to a 7% yearly
reduction in the death rate), and the 3-year MRR was 0.94
[95% CI, 0.92 to 0.96] (Supplementary Table 2). All
results were substantially the same when DCOs were
excluded from the DCR data (results not shown).
Discussion
This study showed that the clinical database DaRenCaData
had a high completeness of 88% and a positive predictive
value at 96% in the study period from August 2010 to
December 2015, when using the Danish Cancer Registry
as reference. Furthermore, the completeness increased dur-
ing the period from 82% to 94%, suggesting that an
increasing number of patients with renal cell carcinoma
have their suspected diagnosis confirmed histologically or
cytologically. DaRenCaData made histological or cytolo-
gical diagnosis of renal cell carcinoma mandatory by
August 2012, and the observed increase in completeness
may be a reflection of this request. Most biopsies per-
formed were core biopsies. The main reason for the dis-
agreement between the two registries was that DCR
included a large number of patients without
a histologically or cytologically verified diagnosis regis-
tered in DPR. Indeed, 446 patients who were found only in
the DCR – corresponding to 60% of the total number of
patients with disagreement – did not appear in DPR. These
patients were older and only had a diagnosis based on
imaging, representing either small indolent lesions, subject
to watchful waiting, or aggressive lesions in frail elderly
patients, unfit for treatment, non-renal cancer carcinoma
neoplasia, or non-malignant lesions. The 24 patients (14%)
found in DaRenCaData only, may have been cases identi-
fied by DCR as relapses and therefore not registered in
DCR. In addition to this, 0.4% of the total DCR patient
population were likely to be patients registered from death
certificate only (the so-called DCOs), because the date of
Table 2 Relative Survival Based on Registry Registration for
DCR and DaRenCaData Patient Populations (Model 1), and
Relative Survival for Patients in the Intersection (with Either
DCR or DaRenCaData Date of Diagnosis as Entry Point), or
Only Registered in DCR or DaRenCaData (Model 2)
Relative Survival (95% CI)
1-Year 3-Year 5-Year
Model 1
DCR patient population 81 (79–82) 69 (67–70) 59 (57–61)
DaRenCaData patient population 85 (84–86) 74 (73–76) 65 (63–67)
Model 2
Intersection with DCR date of
diagnosis 86 (85–87) 75 (73–77) 66 (64–68)
Intersection with DaRenCaData
date of diagnosis 86 (85–88) 76 (74–77) 67 (65–69)
Patients only registered in DCR 52 (48–56) 29 (25–34) 21 (17–25)
Patients only registered in
DaRenCaData 64 (56–70) 47 (39–55) 38 (30–46)
Table 3 Mortality Rate Ratios for DCR and DaRenCa Patient Populations (Model 1), and Mortality Rate Ratios for Patients in the
Intersection (with Either DCR or DaRenCa Date of Diagnosis as Entry Point), or Only Registered in DCR or DaRenCaData (Model 2)
HR (95% CI)
1-Year 3-Year 5-Year
Model 1
DCR patient population 1 1 1
DaRenCaData patient population 0.79 (0.72–0.88) 0.84 (0.78–0.91) 0.86 (0.80–0.92)
Model 2
Intersection with DCR date of diagnosis 1 1 1
Intersection with DaRenCaData date of diagnosis 0.98 (0.88–1.10) 0.98 (0.91–1.07) 0.99 (0.92–1.06)
Patients only registered in DCR 4.29 (3.72–4.93) 3.58 (3.18–4.03) 3.27 (2.92–3.66)
Patients only registered in DaRenCaData 2.84 (2.20–3.68) 2.23 (1.78–2.78) 2.03 (1.64–2.51)
Danckert et al Dovepress
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diagnosis was equal to the date of death. Actually, DCR
reports to register in general 0.4% of all incident cancer
cases as DCOs.15 In essence, the main differences between
DaRenCaData and DCR related to diagnoses that had not
been histologically or cytologically verified, as
a consequence of the differences in DaRenCaData and
DCR inclusion criteria. Thus, the high completeness of
DaRenCaData observed in the study period is indeed an
underestimate, as not all patients in DCR should be
included in DaRenCaData.
However, both DaRenCaData and DCR comprised
patients that appeared to be candidates for the other reg-
istry as well. While this may partly be due to minor errors
in their algorithms, some patients may have been excluded
from DCR, because DCR had some observations under
further investigation before decision of inclusion or exclu-
sion (ie, the registration may have been considered incom-
plete). Also, both registries may have excluded some
patients if they were found to have a prior diagnosis of
renal cancer before the present study period. Such patients
may have been registered with a registration of relapse in
DaRenCaData or DNPR prior to the inclusion date.
In general, patients registered in DaRenCaData had
higher relative survival and lower mortality rate ratios
than patients registered in DCR. This finding may reflect
that DaRenCaData used DPR as their primary source,
meaning that only patients with histologically or cytologi-
cally verified diagnosis were included. This may indicate
that patients in DCR without histologically or cytologi-
cally verified diagnoses primarily are patients who were
considered to have a poor prognosis and consequently not
being offered detailed diagnostic work-up; but on the other
hand, some of them may also comprise patients with good
prognosis and a minor lesion too small for biopsy.
Actually, patients in both set differences displayed
significantly higher MRRs and lower relative survival
estimates than patients in the intersection; controlling for
stage did not change our findings. Neither the different
definitions of dates of diagnosis of the two registries nor
DCOs registered in DCR appeared to affect survival mea-
sures to any notable extent. Intriguingly, for both regis-
tries, improved survival for patients with renal cell
carcinoma was observed during the observation period,
corresponding to a 7% yearly reduction in death.
The findings in this study have documented that the
definition of patient populations in DCR and
DaRenCaData has important implications for the survival
measures. This applies to findings in Swedish RCC
national dataset that uses similar definitions.16 The main
reason was that DCR also included patients that have not
had their renal cancer diagnosis histologically or cytologi-
cally verified. While there may be good reasons for choos-
ing either of the two inclusion criteria of the registries, it is
important to be very explicit about the definitions, and
sensitivity analysis using alternative criteria could be per-
formed in order to provide a fuller understanding of the
findings and enable dialogues about the results. The pre-
sent study contributes to the growing literature regarding
assessments of medical databases and their quality, provid-
ing better backgrounds for epidemiological research.
In conclusion, DaRenCaData had a high and increasing
completeness at an average of 88% and high PPV at 96%
compared to DCR, establishing DaRenCaData as a high-
quality research database. In both registries, renal cell
carcinoma mortality declined over time. Patients with
renal cell carcinoma only registered in DCR or
DaRenCaData have poorer outcomes than patients found
in both registries. This study points to the importance of
assessing the inclusion criteria when interpreting registry-
based studies.
Table 4 1-Year Mortality Rate Ratios with Time Variations for Patients Registered in Both DCR and DaRenCaData (Model 2)
Number of Deaths 1-Year Mortality Rate Ratio (95% CI)
Time measured as a categorical variable
Period 1 (August 2010 – July 2011) 124 [Reference category]
Period 2 (August 2011 – July 2012) 127 1.04 (0.89–1.22)
Period 3 (August 2012 – July 2013) 120 0.84 (0.71–0.99)
Period 4 (August 2013 – July 2014) 127 0.82 (0.70–0.96)
Period 5 (August 2014 – July 2015) 133 0.74 (0.63–0.87)
Period 6 (August 2015 – December 2015) 58 0.74 (0.60–0.91)
Time measured as a continuous variable
Years between date of diagnosis and start of observation period (August 1st 2010) – 0.93 (0.90–0.96)
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